3-氨基-4,4-二苯基丁酸

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-4,4-二苯基丁酸
• 英文名称: 3-azaniumyl-4,4-diphenylbutanoate
• 化学式: C16H17NO2
• mdl: MFCD06205259
• 分子量: 255.31
• InChiKey: BMWWMUHNEWGJJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.187
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents
  申请人：METHYLGENE INC.

  公开号：US20140081017A1

  公开（公告）日：2014-03-20

  The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, the invention relates to compounds, compositions thereof, and methods for selectively enhancing fungal sensitivity to antifungal compounds. The compositions of the invention are comprised of a combination of a histone deacetylase inhibitor, or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt, agricultural formulation, prodrug or complex thereof, and an antifungal agent, the histone deacetylase inhibitor being a compound of Formula (I):

  本发明涉及用于选择性治疗真菌感染的组合物和方法。更具体地，本发明涉及化合物、其组合物以及用于增强真菌对抗真菌化合物敏感性的方法。本发明的组合物由组成，其中组脱乙酰酶抑制剂的组合物，或N-氧化物、水合物、溶剂化合物、药用可接受盐、农药配方、前药或其复合物，以及抗真菌剂，其中组脱乙酰酶抑制剂为式(I)的化合物：
• Tripeptide prodrug compounds
  申请人：——

  公开号：US20030181359A1

  公开（公告）日：2003-09-25

  The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.

  本发明的前药是治疗剂的改良形式，包括治疗剂，三个氨基酸的寡肽，稳定基团和可选的连接基团。前药可被Thimet寡肽酶等水解酶酶解。还公开了制备和使用前药化合物的方法。
• CD10-activated prodrug compounds
  申请人：——

  公开号：US20040087497A1

  公开（公告）日：2004-05-06

  The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.

  本发明的化合物是治疗剂的改良形式。本发明的典型前药化合物包括治疗剂、寡肽、稳定基和可选的连接基。该前药可被CD10酶水解。本发明还揭示了使用前药进行治疗的方法和设计前药的方法。
• CD-10 activated prodrug compounds
  申请人：Bebbington R. Christopher

  公开号：US20050267016A1

  公开（公告）日：2005-12-01

  The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.

  该发明的化合物是治疗剂的改良形式。该发明的典型前药化合物包括治疗剂、寡肽、稳定基和可选的连接基。该前药可被CD10酶剪切。该文还公开了使用前药进行治疗的方法和设计前药的方法。
• Enzyme-cleavable prodrug compounds
  申请人：——

  公开号：US20020142955A1

  公开（公告）日：2002-10-03

  The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.

  本发明的前药是治疗剂的改良形式，包括治疗剂、寡肽、稳定基团和可选的连接基团。该前药可被Thimet寡肽酶或TOP酶水解。本发明还揭示了通过利用共轭物中可被TOP酶水解的序列设计前药的方法以及使用本发明的前药治疗患者的方法。